Cargando…
Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Singapore
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895077/ https://www.ncbi.nlm.nih.gov/pubmed/34562260 http://dx.doi.org/10.1007/s12282-021-01296-z |
| _version_ | 1784662832964435968 |
|---|---|
| author | Taira, Naruto Kashiwabara, Kosuke Tsurutani, Junji Kitada, Masahiro Takahashi, Masato Kato, Hiroaki Kikawa, Yuichiro Sakata, Eiko Naito, Yoichi Hasegawa, Yoshie Saito, Tsuyoshi Iwasa, Tsutomu Takashima, Tsutomu Aihara, Tomohiko Mukai, Hirofumi Hara, Fumikata |
| author_facet | Taira, Naruto Kashiwabara, Kosuke Tsurutani, Junji Kitada, Masahiro Takahashi, Masato Kato, Hiroaki Kikawa, Yuichiro Sakata, Eiko Naito, Yoichi Hasegawa, Yoshie Saito, Tsuyoshi Iwasa, Tsutomu Takashima, Tsutomu Aihara, Tomohiko Mukai, Hirofumi Hara, Fumikata |
| author_sort | Taira, Naruto |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8895077 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Singapore |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88950772022-03-04 Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer Taira, Naruto Kashiwabara, Kosuke Tsurutani, Junji Kitada, Masahiro Takahashi, Masato Kato, Hiroaki Kikawa, Yuichiro Sakata, Eiko Naito, Yoichi Hasegawa, Yoshie Saito, Tsuyoshi Iwasa, Tsutomu Takashima, Tsutomu Aihara, Tomohiko Mukai, Hirofumi Hara, Fumikata Breast Cancer Correction Springer Singapore 2021-09-25 2022 /pmc/articles/PMC8895077/ /pubmed/34562260 http://dx.doi.org/10.1007/s12282-021-01296-z Text en © The Japanese Breast Cancer Society 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Correction Taira, Naruto Kashiwabara, Kosuke Tsurutani, Junji Kitada, Masahiro Takahashi, Masato Kato, Hiroaki Kikawa, Yuichiro Sakata, Eiko Naito, Yoichi Hasegawa, Yoshie Saito, Tsuyoshi Iwasa, Tsutomu Takashima, Tsutomu Aihara, Tomohiko Mukai, Hirofumi Hara, Fumikata Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer |
| title | Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer |
| title_full | Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer |
| title_fullStr | Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer |
| title_full_unstemmed | Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer |
| title_short | Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer |
| title_sort | correction to: quality of life in a randomized phase ii study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895077/ https://www.ncbi.nlm.nih.gov/pubmed/34562260 http://dx.doi.org/10.1007/s12282-021-01296-z |
| work_keys_str_mv | AT tairanaruto correctiontoqualityoflifeinarandomizedphaseiistudytodeterminetheoptimaldoseof3weekcyclenabpaclitaxelinpatientswithmetastaticbreastcancer AT kashiwabarakosuke correctiontoqualityoflifeinarandomizedphaseiistudytodeterminetheoptimaldoseof3weekcyclenabpaclitaxelinpatientswithmetastaticbreastcancer AT tsurutanijunji correctiontoqualityoflifeinarandomizedphaseiistudytodeterminetheoptimaldoseof3weekcyclenabpaclitaxelinpatientswithmetastaticbreastcancer AT kitadamasahiro correctiontoqualityoflifeinarandomizedphaseiistudytodeterminetheoptimaldoseof3weekcyclenabpaclitaxelinpatientswithmetastaticbreastcancer AT takahashimasato correctiontoqualityoflifeinarandomizedphaseiistudytodeterminetheoptimaldoseof3weekcyclenabpaclitaxelinpatientswithmetastaticbreastcancer AT katohiroaki correctiontoqualityoflifeinarandomizedphaseiistudytodeterminetheoptimaldoseof3weekcyclenabpaclitaxelinpatientswithmetastaticbreastcancer AT kikawayuichiro correctiontoqualityoflifeinarandomizedphaseiistudytodeterminetheoptimaldoseof3weekcyclenabpaclitaxelinpatientswithmetastaticbreastcancer AT sakataeiko correctiontoqualityoflifeinarandomizedphaseiistudytodeterminetheoptimaldoseof3weekcyclenabpaclitaxelinpatientswithmetastaticbreastcancer AT naitoyoichi correctiontoqualityoflifeinarandomizedphaseiistudytodeterminetheoptimaldoseof3weekcyclenabpaclitaxelinpatientswithmetastaticbreastcancer AT hasegawayoshie correctiontoqualityoflifeinarandomizedphaseiistudytodeterminetheoptimaldoseof3weekcyclenabpaclitaxelinpatientswithmetastaticbreastcancer AT saitotsuyoshi correctiontoqualityoflifeinarandomizedphaseiistudytodeterminetheoptimaldoseof3weekcyclenabpaclitaxelinpatientswithmetastaticbreastcancer AT iwasatsutomu correctiontoqualityoflifeinarandomizedphaseiistudytodeterminetheoptimaldoseof3weekcyclenabpaclitaxelinpatientswithmetastaticbreastcancer AT takashimatsutomu correctiontoqualityoflifeinarandomizedphaseiistudytodeterminetheoptimaldoseof3weekcyclenabpaclitaxelinpatientswithmetastaticbreastcancer AT aiharatomohiko correctiontoqualityoflifeinarandomizedphaseiistudytodeterminetheoptimaldoseof3weekcyclenabpaclitaxelinpatientswithmetastaticbreastcancer AT mukaihirofumi correctiontoqualityoflifeinarandomizedphaseiistudytodeterminetheoptimaldoseof3weekcyclenabpaclitaxelinpatientswithmetastaticbreastcancer AT harafumikata correctiontoqualityoflifeinarandomizedphaseiistudytodeterminetheoptimaldoseof3weekcyclenabpaclitaxelinpatientswithmetastaticbreastcancer |